🟢 Neumora Therapeutics is trading 6.77% up in pre-market with no clear company-specific catalyst identified

Neumora Therapeutics is trading at $1.42 (+6.77%) in pre-market on September 1, 2026, with no clear company-specific catalyst identified.

• The latest official investor-relations release remains the August 14, 2026 second-quarter update, covering leadership and pipeline developments.
• An SEC filing states Joshua Pinto’s CEO transition became effective August 14, not September 1.
• Broader indexes are lower, so market sentiment does not explain the gain.